Factors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancer

Factors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancer

Objective: to evaluate tolerability and efficacy of maintenance treatment in the absence of progression after 16 weeks of first-line therapy in patients with unresectable metastatic colon cancer.Materials and methods. We have analyzed medical case histories of patients with metastatic colorectal can...

Full description

Bibliographic Details
Main Authors:	M. Yu. Fedyanin, A. A. Tryakin, E. M. Polyanskaya, I. A. Pokataev, O. V. Sheina, N. A. Kozlov, A. M. Strogonova, S. S. Gordeev, D. V. Kuz’michev, V. A. Aliev, I. V. Sagaydak, S. A. Rasulov, S. A. Tyulandin
Format:	Article
Language:	Russian
Published:	“ABV-press” Publishing house”, LLC 2016-08-01
Series:	Тазовая хирургия и онкология
Subjects:	colon cancer unresectable metastases maintenance chemotherapy first-line therapy second-line therapy progression-free survival fluoropyrimidines
Online Access:	https://ok.abvpress.ru/jour/article/view/168

Similar Items

Irinotecan in the treatment of colorectal cancer. A literature review
by: V. A. Ivanov, et al.
Published: (2017-04-01)

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia
by: N. S. Besova, et al.
Published: (2019-12-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY
by: M. Yu. Fedyanin, et al.
Published: (2015-05-01)

FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study
by: M. Yu. Fedyanin, et al.
Published: (2019-11-01)

Folinic Acid Enhanced Cytotoxicity of Fluoropyrimidines In Human Breast Cancer Cells
by: Mandelbaum-Shavit Frederika
Published: (1993-02-01)

BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
by: T. A. Malysheva, et al.
Published: (2015-02-01)

The role of surgery for anaplastic thyroid carcinoma in the era of targeted therapeutics: A scoping review
by: Eoin F. Cleere, et al.
Published: (2023-12-01)

Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma
by: Zhu Ji, et al.
Published: (2013-01-01)

TEYSUNO: FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH DISSEMINATED GASTRIC CANCER
by: O. O. GORDEEVA, et al.
Published: (2017-06-01)

FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
by: N. V. Dobrova, et al.
Published: (2018-02-01)

Chronic lymphocytic leukemia/small lymphocytic lymphoma
by: E. A. Nikitin, et al.
Published: (2020-11-01)

EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
by: N. Z. Sherman, et al.
Published: (2015-02-01)

The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases
by: Elizaveta M. Polyanskaya, et al.
Published: (2023-05-01)

First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
by: Wenfeng Liu, et al.
Published: (2021-12-01)

Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
by: Zhang Mengqi, et al.
Published: (2023-11-01)

A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern
by: Kathleen Kerrigan, DO, et al.
Published: (2022-03-01)

Investigation of tumor tissue alteration after experimental chemotherapy
by: Grygorieva E. V.
Published: (2009-01-01)

Methods of reconstruction of perineal wounds after abdominoperineal resection. Literature review
by: S. S. Gordeev, et al.
Published: (2017-09-01)

Optimal number of lymph nodes to be examined in stage II colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2019-06-01)

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib
by: Makoto Endo, et al.
Published: (2023-03-01)

Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis
by: Rong-xin Zhang, et al.
Published: (2017-07-01)

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
by: Cobo M, et al.
Published: (2017-07-01)

Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients
by: Mariam A. Fouad, et al.
Published: (2018-10-01)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
by: Jing Yuan, et al.
Published: (2022-06-01)

Clinical example of long-term control of disseminated signet-ring cell carcinoma of the stomach against the background of chemotherapy of the second line of treatment in combination with bevacizumab
by: T. A. Titova, et al.
Published: (2019-12-01)

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies
by: Chen Liang, et al.
Published: (2023-12-01)

Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
by: Yin Long, et al.
Published: (2023-12-01)

Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy
by: Bahareh Farasati Far, et al.
Published: (2023-03-01)

First line therapy of metastatic urothelial bladder cancer
by: Lorena Stamičar, et al.
Published: (2021-01-01)

Colorectal cancer with synchronous lung metastases: clinical characteristics, treatment, prognosis
by: A. O. Rasulov, et al.
Published: (2016-04-01)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
by: Nan Jiang, et al.
Published: (2023-07-01)

Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases
by: Mingzhu Huang, et al.
Published: (2022-01-01)

Esophageal stenting for unresectable cancer (review of literature)
by: N. S. Popova, et al.
Published: (2021-01-01)

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
by: Zuoyao Long, et al.
Published: (2023-01-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Отдаленные результаты хирургического и комбинированного лечения больных раком верхнеампулярного отдела прямой кишки
by: Zh. M. Mad’yarov, et al.
Published: (2016-08-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
by: Linda Cucciniello, et al.
Published: (2022-09-01)

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
by: Ignacio Romero, et al.
Published: (2024-01-01)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
by: Domenica Lorusso, et al.
Published: (2022-03-01)